This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

The future of personalized and targeted cancer therapy

April 5th, 2013

Harnessing the patient's own immune system to fight cancer through genetic modification of their own cells is rapidly emerging as a promising treatment option. Although these therapies provide great opportunities, they also pose unique challenges as investigators seek to refine the approach and expand the treatment option to more patients. A panel discussion at the AACR Annual Meeting 2013 – featuring the University of Pennsylvania physician-scientist leading the research team whose work has spurred worldwide attention to chimeric antigen receptor (CAR) technologies, and a trial participant whose leukemia remains in remission more than two and a half years after being treated with his own engineered cells – will explore the future of personalized cellular therapies.

WHERE:

AACR Annual Meeting 2013

Room 150

Walter E. Washington Convention Center

801 Mt Vernon Pl NW

Washington, DC 20001

WHEN:

Sunday, April 7, 2013

1 to 3 PM EDT

WHO:
— Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the Perelman School of Medicine at the University of Pennsylvania and the director of Translational Research in the Abramson Cancer Center
— Douglas Olson, PhD, Penn Medicine modified T cell trial participant

Provided by University of Pennsylvania School of Medicine

Citation: The future of personalized and targeted cancer therapy (2013, April 5) retrieved 31 July 2026 from https://sciencex.com/wire-news/126623348/the-future-of-personalized-and-targeted-cancer-therapy.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.